NASDAQ:CERS Cerus (CERS) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free CERS Stock Alerts $1.86 -0.05 (-2.62%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.86▼$1.9350-Day Range$1.66▼$2.4252-Week Range$1.21▼$3.08Volume1.51 million shsAverage Volume1.32 million shsMarket Capitalization$337.18 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cerus alerts: Email Address Cerus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside47.8% Upside$2.75 Price TargetShort InterestHealthy2.48% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 20 Articles This WeekInsider TradingSelling Shares$372,912 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.10) to ($0.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector603rd out of 947 stocksSurgical & Medical Instruments Industry65th out of 99 stocks 3.3 Analyst's Opinion Consensus RatingCerus has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.75, Cerus has a forecasted upside of 47.8% from its current price of $1.86.Amount of Analyst CoverageCerus has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.48% of the outstanding shares of Cerus have been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cerus has recently increased by 4.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERS. Previous Next 1.9 News and Social Media Coverage News SentimentCerus has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Cerus this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CERS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cerus to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $372,912.00 in company stock.Percentage Held by InsidersOnly 7.05% of the stock of Cerus is held by insiders.Percentage Held by Institutions81.72% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.10) to ($0.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -8.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -8.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 6.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Cerus Stock (NASDAQ:CERS)Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.Read More CERS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERS Stock News HeadlinesMarch 15, 2024 | insidertrades.comCerus Co. (NASDAQ:CERS) Insider Chrystal Jensen Sells 17,460 SharesMarch 12, 2024 | insidertrades.comCerus Co. (NASDAQ:CERS) Insider Richard J. Benjamin Sells 29,378 SharesMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 16, 2024 | americanbankingnews.comWilliam Mariner Greenman Sells 62,315 Shares of Cerus Co. (NASDAQ:CERS) StockMarch 16, 2024 | americanbankingnews.comCarol Moore Sells 20,619 Shares of Cerus Co. (NASDAQ:CERS) StockMarch 16, 2024 | americanbankingnews.comKevin Dennis Green Sells 21,497 Shares of Cerus Co. (NASDAQ:CERS) StockMarch 16, 2024 | americanbankingnews.comChrystal Jensen Sells 17,460 Shares of Cerus Co. (NASDAQ:CERS) StockMarch 16, 2024 | americanbankingnews.comVivek K. Jayaraman Sells 26,247 Shares of Cerus Co. (NASDAQ:CERS) StockMarch 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 16, 2024 | ca.finance.yahoo.comCERS Apr 2024 3.000 callMarch 15, 2024 | finance.yahoo.comInsider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS)March 15, 2024 | finance.yahoo.comInsider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS)March 9, 2024 | americanbankingnews.comCerus (NASDAQ:CERS) Stock Rating Reaffirmed by StephensMarch 8, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their Cerus Corporation (NASDAQ:CERS) Price Target To US$4.13March 7, 2024 | finance.yahoo.comCerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comCerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA BreakevenMarch 7, 2024 | seekingalpha.comCerus Corporation (CERS) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comCerus Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 6, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Cerus (CERS)March 6, 2024 | finance.yahoo.comQ4 2023 Cerus Corp Earnings CallMarch 6, 2024 | gurufocus.comQ4 2023 Cerus Corp Earnings Call TranscriptMarch 5, 2024 | investorplace.comCERS Stock Earnings: Cerus Beats EPS, Misses Revenue for Q4 2023March 5, 2024 | businesswire.comCerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial ResultsMarch 5, 2024 | businesswire.comCerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial ResultsMarch 4, 2024 | benzinga.comCerus's Earnings: A PreviewFebruary 20, 2024 | finance.yahoo.comCerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024February 20, 2024 | businesswire.comCerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024See More Headlines Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:CERS CUSIP15708510 CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees665Year Founded1991Price Target and Rating Average Stock Price Target$2.75 High Stock Price Target$3.00 Low Stock Price Target$2.50 Potential Upside/Downside+47.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,490,000.00 Net Margins-23.98% Pretax Margin-19.98% Return on Equity-67.17% Return on Assets-17.68% Debt Debt-to-Equity Ratio1.12 Current Ratio2.14 Quick Ratio1.55 Sales & Book Value Annual Sales$156.37 million Price / Sales2.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book6.41Miscellaneous Outstanding Shares181,280,000Free Float168,503,000Market Cap$337.18 million OptionableOptionable Beta1.31 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. William M. Greenman (Age 57)President, CEO & Director Comp: $1.33MMr. Kevin D. Green (Age 52)VP of Finance & CFO Comp: $748.49kMr. Vivek K. Jayaraman (Age 49)Chief Operating Officer Comp: $861.67kMs. Chrystal Jensen (Age 53)Chief Legal Officer & General Counsel Comp: $692.16kDr. Richard J. Benjamin (Age 64)Chief Medical Officer Comp: $719.74kDr. Laurence M. Corash (Age 80)Co-Founder & Chief Scientific Officer Comp: $697.77kMs. Lori L. RollVP of Administration & Corporate SecretaryMr. Matthew M. NotarianniSenior Director of Investor RelationsLainie CortenVice President of Global MarketingMs. Alicia GoodmanChief Human Resources OfficerMore ExecutivesKey CompetitorsAnika TherapeuticsNASDAQ:ANIKInovio PharmaceuticalsNASDAQ:INOUtah Medical ProductsNASDAQ:UTMDOraSure TechnologiesNASDAQ:OSURAtrionNASDAQ:ATRIView All CompetitorsInsiders & InstitutionsKevin Dennis GreenSold 21,497 sharesTotal: $42,349.09 ($1.97/share)William Mariner GreenmanSold 62,315 sharesTotal: $128,368.90 ($2.06/share)Vivek K JayaramanSold 26,247 sharesTotal: $54,068.82 ($2.06/share)Chrystal JensenSold 17,460 sharesTotal: $35,967.60 ($2.06/share)Carol MooreSold 20,619 sharesTotal: $41,650.38 ($2.02/share)View All Insider TransactionsView All Institutional Transactions CERS Stock Analysis - Frequently Asked Questions Should I buy or sell Cerus stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CERS shares. View CERS analyst ratings or view top-rated stocks. What is Cerus' stock price target for 2024? 2 brokerages have issued 1 year price targets for Cerus' shares. Their CERS share price targets range from $2.50 to $3.00. On average, they anticipate the company's share price to reach $2.75 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price. View analysts price targets for CERS or view top-rated stocks among Wall Street analysts. How have CERS shares performed in 2024? Cerus' stock was trading at $2.16 at the start of the year. Since then, CERS shares have decreased by 13.9% and is now trading at $1.86. View the best growth stocks for 2024 here. When is Cerus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CERS earnings forecast. How were Cerus' earnings last quarter? Cerus Co. (NASDAQ:CERS) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. The biotechnology company earned $36.13 million during the quarter, compared to analysts' expectations of $31.60 million. Cerus had a negative net margin of 23.98% and a negative trailing twelve-month return on equity of 67.17%. During the same quarter in the previous year, the company earned ($0.08) EPS. What ETFs hold Cerus' stock? ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ARK Innovation ETF (ARKK). What guidance has Cerus issued on next quarter's earnings? Cerus issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $172.0 million-$175.0 million, compared to the consensus revenue estimate of $185.9 million. What is William M. (Obi) Greenman's approval rating as Cerus' CEO? 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA). Who are Cerus' major shareholders? Cerus' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.54%), Vanguard Group Inc. (5.45%), Vanguard Group Inc. (5.44%), Sumitomo Mitsui Trust Holdings Inc. (4.18%), Nikko Asset Management Americas Inc. (4.18%) and Senvest Management LLC (3.63%). Insiders that own company stock include Ann Lucena, Carol Moore, Chrystal Jensen, Chrystal Menard, Daniel N Swisher Jr, Eric Bjerkholt, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Vivek K Jayaraman and William Mariner Greenman. View institutional ownership trends. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CERS) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.